MedTrace Logo

Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

NCT03383276 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-12-26

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of ocular administration of Topical Interleukin-1-Receptor Antagonist in healthy volunteers. Additionally, the PK of Interleukin-1-Receptor Antagonist will be assessed.

Conditions

  • Blepharokeratoconjunctivitis

Interventions

DRUG

IL-1Ra

custom eye drop to be applied to the left eye.

Sponsors & Collaborators

  • Chengdu Rhodiola Bio-Pharmaceutical Co Ltd

    collaborator INDUSTRY

  • Beijing Tongren Hospital

    lead OTHER

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-18
Primary Completion
2018-03-25
Completion
2018-06-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03383276 on ClinicalTrials.gov